Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 328

1.

Association of metformin with breast cancer incidence and mortality in patients with type 2 diabetes: a GRADE assessed systematic review and meta-analysis.

Tang GH, Satkunam M, Pond GR, Steinberg GR, Blandino G, Schünemann HJ, Muti P.

Cancer Epidemiol Biomarkers Prev. 2018 Apr 4. pii: cebp.0936.2017. doi: 10.1158/1055-9965.EPI-17-0936. [Epub ahead of print]

PMID:
29618465
2.

Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma.

Di Agostino S, Valenti F, Sacconi A, Fontemaggi G, Pallocca M, Pulito C, Ganci F, Muti P, Strano S, Blandino G.

Theranostics. 2018 Feb 12;8(7):1850-1868. doi: 10.7150/thno.22167. eCollection 2018.

3.

New therapeutic strategies to treat human cancers expressing mutant p53 proteins.

Blandino G, Di Agostino S.

J Exp Clin Cancer Res. 2018 Feb 15;37(1):30. doi: 10.1186/s13046-018-0705-7. Review.

4.

hMENA is a key regulator in endothelin-1/β-arrestin1-induced invadopodial function and metastatic process.

Di Modugno F, Caprara V, Chellini L, Tocci P, Spadaro F, Ferrandina G, Sacconi A, Blandino G, Nisticò P, Bagnato A, Rosanò L.

Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):3132-3137. doi: 10.1073/pnas.1715998115. Epub 2018 Feb 8.

5.

Che-1 is targeted by c-Myc to sustain proliferation in pre-B-cell acute lymphoblastic leukemia.

Folgiero V, Sorino C, Pallocca M, De Nicola F, Goeman F, Bertaina V, Strocchio L, Romania P, Pitisci A, Iezzi S, Catena V, Bruno T, Strimpakos G, Passananti C, Mattei E, Blandino G, Locatelli F, Fanciulli M.

EMBO Rep. 2018 Mar;19(3). pii: e44871. doi: 10.15252/embr.201744871. Epub 2018 Jan 24.

PMID:
29367285
6.

HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.

di Martino S, Amoreo CA, Nuvoli B, Galati R, Strano S, Facciolo F, Alessandrini G, Pass HI, Ciliberto G, Blandino G, De Maria R, Cioce M.

Oncogene. 2018 Mar;37(10):1369-1385. doi: 10.1038/s41388-017-0044-8. Epub 2018 Jan 9.

PMID:
29311642
7.

Immunomodulatory Effects of Bifidobacterium longum W11 Produced Exopolysaccharide on Cytokine Production.

Inturri R, Mangano K, Santagati M, Intrieri M, Di Marco R, Blandino G.

Curr Pharm Biotechnol. 2017;18(11):883-889. doi: 10.2174/1389201019666171226151551.

PMID:
29278212
8.

The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex.

Verduci L, Ferraiuolo M, Sacconi A, Ganci F, Vitale J, Colombo T, Paci P, Strano S, Macino G, Rajewsky N, Blandino G.

Genome Biol. 2017 Dec 20;18(1):237. doi: 10.1186/s13059-017-1368-y.

9.

MicroRNA-128-3p-mediated depletion of Drosha promotes lung cancer cell migration.

Frixa T, Sacconi A, Cioce M, Roscilli G, Ferrara FF, Aurisicchio L, Pulito C, Telera S, Carosi M, Muti P, Strano S, Donzelli S, Blandino G.

Carcinogenesis. 2018 Feb 9;39(2):293-304. doi: 10.1093/carcin/bgx134.

PMID:
29236960
10.

Epigenetic silencing of miR-296 and miR-512 ensures hTERT dependent apoptosis protection and telomere maintenance in basal-type breast cancer cells.

Dinami R, Buemi V, Sestito R, Zappone A, Ciani Y, Mano M, Petti E, Sacconi A, Blandino G, Giacca M, Piazza S, Benetti R, Schoeftner S.

Oncotarget. 2017 Sep 23;8(56):95674-95691. doi: 10.18632/oncotarget.21180. eCollection 2017 Nov 10.

11.

MiRNA-513a-5p inhibits progesterone receptor expression and constitutes a risk factor for breast cancer: the hOrmone and Diet in the ETiology of breast cancer prospective study.

Muti P, Donzelli S, Sacconi A, Hossain A, Ganci F, Frixa T, Sieri S, Krogh V, Berrino F, Biagioni F, Strano S, Beyene J, Yarden Y, Blandino G.

Carcinogenesis. 2018 Feb 9;39(2):98-108. doi: 10.1093/carcin/bgx126.

PMID:
29126102
12.

Melatonin and Hippo Pathway: Is There Existing Cross-Talk?

Lo Sardo F, Muti P, Blandino G, Strano S.

Int J Mol Sci. 2017 Sep 6;18(9). pii: E1913. doi: 10.3390/ijms18091913.

13.

Chemical and biological properties of the novel exopolysaccharide produced by a probiotic strain of Bifidobacterium longum.

Inturri R, Molinaro A, Di Lorenzo F, Blandino G, Tomasello B, Hidalgo-Cantabrana C, De Castro C, Ruas-Madiedo P.

Carbohydr Polym. 2017 Oct 15;174:1172-1180. doi: 10.1016/j.carbpol.2017.07.039. Epub 2017 Jul 19.

PMID:
28821042
14.

Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress.

Masciarelli S, Capuano E, Ottone T, Divona M, De Panfilis S, Banella C, Noguera NI, Picardi A, Fontemaggi G, Blandino G, Lo-Coco F, Fazi F.

Leukemia. 2018 Feb;32(2):285-294. doi: 10.1038/leu.2017.231. Epub 2017 Aug 4.

15.

Altered peritumoral microRNA expression predicts head and neck cancer patients with a high risk of recurrence.

Ganci F, Sacconi A, Manciocco V, Covello R, Benevolo M, Rollo F, Strano S, Valsoni S, Bicciato S, Spriano G, Muti P, Fontemaggi G, Blandino G.

Mod Pathol. 2017 Oct;30(10):1387-1401. doi: 10.1038/modpathol.2017.62. Epub 2017 Jul 21.

PMID:
28731048
16.

MicroRNAs as Key Effectors in the p53 Network.

Goeman F, Strano S, Blandino G.

Int Rev Cell Mol Biol. 2017;333:51-90. doi: 10.1016/bs.ircmb.2017.04.003. Epub 2017 May 22. Review.

PMID:
28729028
17.

Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities.

Pulito C, Mori F, Sacconi A, Goeman F, Ferraiuolo M, Pasanisi P, Campagnoli C, Berrino F, Fanciulli M, Ford RJ, Levrero M, Pediconi N, Ciuffreda L, Milella M, Steinberg GR, Cioce M, Muti P, Strano S, Blandino G.

Cell Discov. 2017 Jul 4;3:17022. doi: 10.1038/celldisc.2017.22. eCollection 2017.

18.

The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1.

Pruszko M, Milano E, Forcato M, Donzelli S, Ganci F, Di Agostino S, De Panfilis S, Fazi F, Bates DO, Bicciato S, Zylicz M, Zylicz A, Blandino G, Fontemaggi G.

EMBO Rep. 2017 Aug;18(8):1331-1351. doi: 10.15252/embr.201643370. Epub 2017 Jun 26.

PMID:
28652379
19.

In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells.

Rizzo A, Donzelli S, Girgenti V, Sacconi A, Vasco C, Salmaggi A, Blandino G, Maschio M, Ciusani E.

J Exp Clin Cancer Res. 2017 Jun 6;36(1):76. doi: 10.1186/s13046-017-0546-9.

20.

AMPK β1 reduces tumor progression and improves survival in p53 null mice.

Houde VP, Donzelli S, Sacconi A, Galic S, Hammill JA, Bramson JL, Foster RA, Tsakiridis T, Kemp BE, Grasso G, Blandino G, Muti P, Steinberg GR.

Mol Oncol. 2017 Sep;11(9):1143-1155. doi: 10.1002/1878-0261.12079. Epub 2017 Jun 28.

21.

Adjuvant intraoperative radiotherapy for selected breast cancers in previously irradiated women: Evidence for excellent feasibility and favorable outcomes.

Blandino G, Guenzi M, Belgioia L, Bonzano E, Configliacco E, Tornari E, Cavagnetto F, Bosetti D, Fozza A, Friedman D, Corvò R.

Rep Pract Oncol Radiother. 2017 Jul-Aug;22(4):277-283. doi: 10.1016/j.rpor.2017.02.009. Epub 2017 May 5.

PMID:
28507456
22.

Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.

Bellissimo T, Ganci F, Gallo E, Sacconi A, Tito C, De Angelis L, Pulito C, Masciarelli S, Diso D, Anile M, Petrozza V, Giangaspero F, Pescarmona E, Facciolo F, Venuta F, Marino M, Blandino G, Fazi F.

Mol Cancer. 2017 May 10;16(1):88. doi: 10.1186/s12943-017-0655-2.

23.

E6AP promotes prostate cancer by reducing p27 expression.

Raghu D, Paul PJ, Gulati T, Deb S, Khoo C, Russo A, Gallo E, Blandino G, Chan AL, Takano E, Sandhu SK, Fox SB, Williams S, Haupt S, Gamell C, Haupt Y.

Oncotarget. 2017 Jun 27;8(26):42939-42948. doi: 10.18632/oncotarget.17224.

24.

Down-regulated miRs specifically correlate with non-cardial gastric cancers and Lauren's classification system.

Lorenzon L, Cippitelli C, Avantifiori R, Uccini S, French D, Torrisi MR, Ranieri D, Mercantini P, Canu V, Blandino G, Cavallini M.

J Surg Oncol. 2017 Aug;116(2):184-194. doi: 10.1002/jso.24648. Epub 2017 May 5.

PMID:
28475823
25.

Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.

Ferraiuolo M, Verduci L, Blandino G, Strano S.

Int J Mol Sci. 2017 May 3;18(5). pii: E961. doi: 10.3390/ijms18050961. Review.

26.

Complete Genome Sequence of Bifidobacterium longum W11 (LMG P-21586), Used as a Probiotic Strain.

Inturri R, Ventura M, Ruas-Madiedo P, Lugli GA, Blandino G.

Genome Announc. 2017 Mar 9;5(10). pii: e01659-16. doi: 10.1128/genomeA.01659-16.

27.

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.

Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, Bazzichetto C, Corbo V, Simbolo M, Sperduti I, Benfante A, Del Curatolo A, Cesta Incani U, Malusa F, Eramo A, Sette G, Scarpa A, Konopleva M, Andreeff M, McCubrey JA, Blandino G, Todaro M, Stassi G, De Maria R, Cognetti F, Del Bufalo D, Ciuffreda L.

Sci Rep. 2017 Feb 21;7:43013. doi: 10.1038/srep43013.

28.

Che-1 sustains hypoxic response of colorectal cancer cells by affecting Hif-1α stabilization.

Bruno T, Valerio M, Casadei L, De Nicola F, Goeman F, Pallocca M, Catena V, Iezzi S, Sorino C, Desantis A, Manetti C, Blandino G, Floridi A, Fanciulli M.

J Exp Clin Cancer Res. 2017 Feb 18;36(1):32. doi: 10.1186/s13046-017-0497-1.

29.

MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer.

Canu V, Sacconi A, Lorenzon L, Biagioni F, Lo Sardo F, Diodoro MG, Muti P, Garofalo A, Strano S, D'Errico A, Grazi GL, Cioce M, Blandino G.

Oncotarget. 2017 May 2;8(18):29540-29557. doi: 10.18632/oncotarget.15290.

30.

Targeting TEAD/YAP-transcription-dependent necrosis, TRIAD, ameliorates Huntington's disease pathology.

Mao Y, Chen X, Xu M, Fujita K, Motoki K, Sasabe T, Homma H, Murata M, Tagawa K, Tamura T, Kaye J, Finkbeiner S, Blandino G, Sudol M, Okazawa H.

Hum Mol Genet. 2016 Nov 1;25(21):4749-4770. doi: 10.1093/hmg/ddw303.

PMID:
28171658
31.

Glypican-1 exosomes: do they initiate a new era for early pancreatic cancer diagnosis?

Lorenzon L, Blandino G.

Transl Gastroenterol Hepatol. 2016 Mar 16;1:8. doi: 10.21037/tgh.2016.01.07. eCollection 2016. No abstract available.

32.
33.

MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer.

Lo Sardo F, Forcato M, Sacconi A, Capaci V, Zanconato F, Di Agostino S, Del Sal G, Pandolfi PP, Strano S, Bicciato S, Blandino G.

Carcinogenesis. 2017 Jan;38(1):64-75. doi: 10.1093/carcin/bgw110. Epub 2016 Oct 17.

PMID:
27797825
34.

Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells.

Catena V, Bruno T, De Nicola F, Goeman F, Pallocca M, Iezzi S, Sorino C, Cigliana G, Floridi A, Blandino G, Fanciulli M.

Oncotarget. 2016 Oct 25;7(43):70546-70558. doi: 10.18632/oncotarget.12060.

35.

Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin.

Pass HI, Lavilla C, Canino C, Goparaju C, Preiss J, Noreen S, Blandino G, Cioce M.

Oncotarget. 2016 Aug 30;7(35):56408-56421. doi: 10.18632/oncotarget.10895.

36.

Editorial: Human Tumor-Derived p53 Mutants: A Growing Family of Oncoproteins.

Haupt Y, Blandino G.

Front Oncol. 2016 Jul 12;6:170. doi: 10.3389/fonc.2016.00170. eCollection 2016. No abstract available.

37.

Dietary Protective Effects Against Hepatocellular Carcinoma Development in Mdr2-/- Knockout Mice.

Gentileschi MP, Lattanzio C, Menicagli F, Vincenzi B, Cigliana G, Baldi A, Blandino G, Muti P, Fanciulli M, Spugnini EP.

In Vivo. 2016 Jul-Aug;30(4):445-50.

PMID:
27381607
38.

Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth.

Aggarwal M, Saxena R, Sinclair E, Fu Y, Jacobs A, Dyba M, Wang X, Cruz I, Berry D, Kallakury B, Mueller SC, Agostino SD, Blandino G, Avantaggiati ML, Chung FL.

Cell Death Differ. 2016 Oct;23(10):1615-27. doi: 10.1038/cdd.2016.48. Epub 2016 Jun 3.

39.

Mir 145/143: tumor suppressor, oncogenic microenvironmental factor or ...both?

Cioce M, Strano S, Muti P, Blandino G.

Aging (Albany NY). 2016 May;8(5):1153-5. doi: 10.18632/aging.100965. No abstract available.

40.

Impact of gut microbiota on diabetes mellitus.

Blandino G, Inturri R, Lazzara F, Di Rosa M, Malaguarnera L.

Diabetes Metab. 2016 Nov;42(5):303-315. doi: 10.1016/j.diabet.2016.04.004. Epub 2016 May 11. Review.

PMID:
27179626
41.

Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition.

Cordani M, Oppici E, Dando I, Butturini E, Dalla Pozza E, Nadal-Serrano M, Oliver J, Roca P, Mariotto S, Cellini B, Blandino G, Palmieri M, Di Agostino S, Donadelli M.

Mol Oncol. 2016 Aug;10(7):1008-29. doi: 10.1016/j.molonc.2016.04.001. Epub 2016 Apr 12.

42.

Delivery of Gemcitabine Prodrugs Employing Mesoporous Silica Nanoparticles.

Malfanti A, Miletto I, Bottinelli E, Zonari D, Blandino G, Berlier G, Arpicco S.

Molecules. 2016 Apr 21;21(4):522. doi: 10.3390/molecules21040522.

43.

Oncogenic Intra-p53 Family Member Interactions in Human Cancers.

Ferraiuolo M, Di Agostino S, Blandino G, Strano S.

Front Oncol. 2016 Mar 31;6:77. doi: 10.3389/fonc.2016.00077. eCollection 2016. Review.

44.

Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects.

Mori F, Ferraiuolo M, Santoro R, Sacconi A, Goeman F, Pallocca M, Pulito C, Korita E, Fanciulli M, Muti P, Blandino G, Strano S.

Oncotarget. 2016 Apr 12;7(15):20532-48. doi: 10.18632/oncotarget.7978.

45.

MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer.

Donzelli S, Cioce M, Muti P, Strano S, Yarden Y, Blandino G.

Semin Cell Dev Biol. 2016 Feb;50:133-42. doi: 10.1016/j.semcdb.2015.12.020. Epub 2016 Jan 7. Review.

PMID:
26773212
46.

Oncogenic MicroRNAs: Key Players in Malignant Transformation.

Frixa T, Donzelli S, Blandino G.

Cancers (Basel). 2015 Dec 18;7(4):2466-85. doi: 10.3390/cancers7040904. Review.

47.

YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins.

Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Bicciato S, Piazza S, Strano S, Del Sal G, Blandino G.

EMBO Rep. 2016 Feb;17(2):188-201. doi: 10.15252/embr.201540488. Epub 2015 Dec 21.

48.

miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma.

Sestito R, Cianfrocca R, Rosanò L, Tocci P, Semprucci E, Di Castro V, Caprara V, Ferrandina G, Sacconi A, Blandino G, Bagnato A.

Oncotarget. 2016 Jan 26;7(4):4009-23. doi: 10.18632/oncotarget.6546.

49.

Labeling quality and molecular characterization studies of products containing Lactobacillus spp. strains.

Blandino G, Fazio D, Petronio GP, Inturri R, Tempera G, Furneri PM.

Int J Immunopathol Pharmacol. 2016 Mar;29(1):121-8. doi: 10.1177/0394632015600534. Epub 2015 Dec 14.

50.

Microbiological characteristics of the probiotic strains B. longum BB536 and L. rhamnosus HN001 used in combination.

Inturri R, Stivala A, Blandino G.

Minerva Gastroenterol Dietol. 2015 Dec;61(4):191-7.

PMID:
26657925

Supplemental Content

Loading ...
Support Center